Pharma Contract Commercialization Market to Reach 5% CAGR by 2029, Boosted by Regulatory and R&D Needs
The Global Pharma Contract Commercialization (CCO) Market is anticipated to grow at a CAGR of 5% by 2029. This growth is driven by several factors including increasing R&D costs, declining pharmaceutical sales, enhanced regulatory scrutiny, and the growing demand for market access, Real-World Evidence (RWE), Health Economics and Outcomes Research (HEOR), pricing and reimbursement, regulatory […]
Continue Reading